Haematopoietic cell transplantation as immunotherapy

The graft-versus-tumour effect seen after allogeneic (genetically different) haematopoietic cell transplantation for human malignancies represents the clearest example of the power of the human immune system to eradicate cancer. Recent advances in our understanding of the immunobiology of stem-cell engraftment, tolerance and tumour eradication are allowing clinicians to better harness this powerful effect.

[1]  E. Goulmy.  Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy , 1997, Immunological reviews.

[2]  A. Barrett,et al.  Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. , 1997, Blood.

[3]  G. Parmiani,et al.  Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  S. Feig,et al.  Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. , 1990, Blood.

[5]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[6]  P. Thall,et al.  Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. , 2001, Blood.

[7]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[8]  J. Bluestone,et al.  CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.

[9]  W. Linehan,et al.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. , 2000, The New England journal of medicine.

[10]  Y. Sonoda,et al.  Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. , 1997, Blood.

[11]  K. Parker,et al.  Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. , 1996, Blood.

[12]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[13]  Steven G.E. Marsh,et al.  Nomenclature for factors of the HLA system , 1975 .

[14]  S. Mackinnon,et al.  T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. , 1998, Blood.

[15]  N. Ueno,et al.  Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Goldman,et al.  Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. , 2000 .

[17]  Peter Parham,et al.  Deconstructing the MHC , 1992, Nature.

[18]  Wei Chen,et al.  CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein. , 1998, Journal of immunotherapy.

[19]  S. Riddell,et al.  Deficient cellular immunity--finding and fixing the defects. , 1999, Science.

[20]  T. Strom,et al.  Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. , 1997, Immunity.

[21]  J. Hoidal,et al.  Structure, chromosomal assignment, and expression of the gene for proteinase-3. The Wegener's granulomatosis autoantigen. , 1992, The Journal of biological chemistry.

[22]  J. Loutit,et al.  Treatment of Murine Leukaemia with X Rays and Homologous Bone Marrow , 1956, British medical journal.

[23]  P. Parham,et al.  Cell-cell adhesion mediated by CD8 and MHC class I molecules , 1988, Nature.

[24]  J. Klein,et al.  The HLA system. First of two parts. , 2000, The New England journal of medicine.

[25]  W R Mayr,et al.  Nomenclature for factors of the HLA system, 1998. , 1999, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[26]  G. Longton,et al.  Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. , 1997, Blood.

[27]  R. Storb,et al.  MARROW GRAFTS BETWEEN DL‐A‐MATCHED CANINE LITTERMATES , 1973, Transplantation.

[28]  R. Storb,et al.  T-cell reconstitution after stem-cell transplantation—by which organ? , 2000, The Lancet.

[29]  Anajane G. Smith,et al.  Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. , 1998, Blood.

[30]  J. Shabanowitz,et al.  The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. , 1998, Science.

[31]  H. Deeg,et al.  Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. , 1992, Blood.

[32]  J. Ritz,et al.  Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. , 1994, Blood.

[33]  P. Linsley,et al.  Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. , 1992, Science.

[34]  C. Craddock,et al.  Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia , 2000 .

[35]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[36]  J. Dick,et al.  CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[37]  K. Sullivan,et al.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.

[38]  Mark M. Davis,et al.  Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia , 2000, Nature Medicine.

[39]  M. Shlomchik,et al.  Prevention of graft versus host disease by inactivation of host antigen-presenting cells. , 1999, Science.

[40]  J. Strominger,et al.  Interaction between CD4 and class II MHC molecules mediates cell adhesion , 1987, Nature.

[41]  M. Gavin,et al.  Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. , 1998, Current opinion in hematology.

[42]  D. Chisholm,et al.  Serum Gastrin in Patients with Peptic Ulceration , 1970, British medical journal.

[43]  F. Appelbaum,et al.  Antibody-targeted therapy for myeloid leukemia. , 1999, Seminars in hematology.

[44]  J. Allison,et al.  CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones , 1992, Nature.

[45]  E. Sotomayor,et al.  Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. , 2000, Blood.

[46]  C. Anasetti,et al.  Anti-CD3ε F(ab′)2 Prevents Graft-Versus-Host Disease by Selectively Depleting Donor T Cells Activated by Recipient Alloantigens1 , 2001, The Journal of Immunology.

[47]  J. Hoidal,et al.  Human Proteinase-3 Expression Is Regulated by PU.1 in Conjunction with a Cytidine-rich Element* , 1996, The Journal of Biological Chemistry.

[48]  R. Henderson,et al.  Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. , 1992, Science.

[49]  High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome , 1997 .

[50]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[51]  R. Storb,et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.

[52]  G. Hill,et al.  Cytokine cascades in acute graft-versus-host disease. , 1997, Transplantation.

[53]  S. Riddell,et al.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.

[54]  Arne Svejgaard,et al.  Nomenclature for Factors of the HLA System, 1998 , 1999, Tissue antigens.

[55]  C. Anasetti,et al.  Role of CD28 in acute graft-versus-host disease. , 1998, Blood.

[56]  C. Anasetti,et al.  CD28-Specific Antibody Prevents Graft-Versus-Host Disease in Mice1 , 2000, The Journal of Immunology.